n-Lorem Foundation Marks Milestone as 50th Nano-Rare Patient Receives Customized ASO Therapy
n-Lorem Foundation Reaches Key Milestone with 50th Nano-Rare Patient Treated Using a Personalized Antisense Oligonucleotide Therapy n-Lorem, a nonprofit foundation dedicated to advancing precision genetic medicine for individuals with ultra-rare…
U.S. Food and Drug Administration Accepts Genentech’s Application for Gazyva in the Treatment of the Most Common Form of Lupus
U.S. Food and Drug Administration Accepts Filing for Genentech’s Gazyva Targeting the Most Prevalent Form of Lupus Genentech, a member of the Roche Group, has announced a major regulatory milestone…
Wound Healing Society Honors Eluciderm, Inc. with Industrial R&D Award for Advancing Research on ELU42’s Mechanism of Action
Wound Healing Society Acknowledges Eluciderm, Inc. with Industrial R&D Award for Advancing ELU42 Mechanism of Action Research Eluciderm, Inc., a clinical-stage biopharmaceutical organization focused on the development of innovative small-molecule…
Annals of Internal Medicine Publishes One-Year Outcomes from LivaNova’s OSPREY Clinical Study in Obstructive Sleep Apnea
Annals of Internal Medicine Reports One-Year Findings from LivaNova’s OSPREY Clinical Trial in Obstructive Sleep Apnea LivaNova PLC (Nasdaq: LIVN) has announced the publication of comprehensive 12-month results from its…
Entos Pharmaceuticals and L-CMD Research Foundation Partner to Advance Curative Therapy for LMNA-Related Congenital Muscular Dystrophy
Entos Pharmaceuticals and L-CMD Research Foundation Join Forces to Develop Curative Therapy for LMNA-Related Congenital Muscular Dystrophy Entos Pharmaceuticals Inc has announced a strategic collaboration with the L-CMD Research Foundation…
Speak Foundation Launches National LGMD Centers of Excellence to Advance Trials and Therapies
Speak Foundation Introduces Patient-Led National LGMD Centers of Excellence to Drive Clinical Trials and Innovative Treatments Speak Foundation has announced the launch of a major new initiative aimed at transforming…
Dana-Farber Study Highlights Predictive Power of Ignite Proteomics’ RPPA Platform for Enhertu® (T-DXd) in Metastatic Breast Cancer
Dana-Farber Study Shows Predictive Potential of Ignite Proteomics’ RPPA Platform for Enhertu® (T-DXd) in Metastatic Breast Cancer Aditxt Inc. has announced a notable scientific and clinical milestone involving its precision…
Palleon Pharmaceuticals Showcases First-in-Class B7-H3–Targeted Sialidase at AACR 2026
Palleon Pharmaceuticals Showcases First-in-Class B7-H3–Targeted Sialidase at AACR 2026 Palleon Pharmaceuticals has unveiled new preclinical findings and announced the initiation of a first-in-human clinical trial for its novel oncology candidate…
Neurogene Names Christy Shafer as Chief Commercial Officer and Adds Christine Mikail, J.D., to Board of Directors
Neurogene Announces Christy Shafer as Chief Commercial Officer and Appoints Christine Mikail, J.D., to Its Board Neurogene Inc. has announced key leadership additions as it advances its mission to develop…
Pulse Biosciences Showcases nPulse™ Technology at Heart Rhythm Society 2026 Annual Meeting
Pulse Biosciences Highlights nPulse™ Technology Presentation at Heart Rhythm Society 2026 Annual Meeting Pulse Biosciences has announced a strong presence at the upcoming Heart Rhythm Society Annual Meeting, where it…
Bicycle Therapeutics Highlights Nuzefatide Pevedotin and EphA2 Pipeline Progress at AACR 2026
Bicycle Therapeutics Shares Pipeline Update on Nuzefatide Pevedotin and EphA2 Programs at AACR 2026 Bicycle Therapeutics has unveiled a comprehensive set of updates from its EphA2-targeting oncology pipeline at the…
RareCyte Advances Clinical-Scale Spatial Proteomics Portfolio with New Orion Systems and Key Leadership Appointment
RareCyte Broadens Clinical-Scale Spatial Proteomics Offering with New Orion Systems and Leadership Addition RareCyte has announced a major expansion of its spatial proteomics capabilities, marking a strategic step forward in…